Ticker: NYSE: BMY
Headquarters: New York City, New York, USA
Founded: 1887 (Bristol-Myers) / 1888 (Squibb)
CEO: Christopher Boerner
Market Cap: ~20B (2026)
Overview
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company committed to discovering, developing, and delivering innovative medicines for patients with serious diseases. The company was formed through the 1989 merger of Bristol-Myers and Squibb Corporation, creating one of the largest pharmaceutical companies in the world. While BMS has historically maintained neuroscience programs, its current neurodegenerative disease portfolio is more limited compared to its dominant positions in oncology, immunology, and cardiovascular diseases[@bms2024].
The company's research strategy has shifted significantly toward immuno-oncology and specialty pharmaceuticals following the landmark acquisition of Celgene in 2019 for $74 billion, which brought multiple high-value pipeline assets including the blockbuster multiple myeloma drug Revlimid (lenalidomide).
2019: Acquisition of Celgene for $74B — largest pharma M&A at the time
2023: Acquisition of Turning Point Therapeutics for $4.1B
Neurodegeneration Pipeline
Historical Programs
...
Ticker: NYSE: BMY
Headquarters: New York City, New York, USA
Founded: 1887 (Bristol-Myers) / 1888 (Squibb)
CEO: Christopher Boerner
Market Cap: ~20B (2026)
Overview
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company committed to discovering, developing, and delivering innovative medicines for patients with serious diseases. The company was formed through the 1989 merger of Bristol-Myers and Squibb Corporation, creating one of the largest pharmaceutical companies in the world. While BMS has historically maintained neuroscience programs, its current neurodegenerative disease portfolio is more limited compared to its dominant positions in oncology, immunology, and cardiovascular diseases[@bms2024].
The company's research strategy has shifted significantly toward immuno-oncology and specialty pharmaceuticals following the landmark acquisition of Celgene in 2019 for $74 billion, which brought multiple high-value pipeline assets including the blockbuster multiple myeloma drug Revlimid (lenalidomide).
2019: Acquisition of Celgene for $74B — largest pharma M&A at the time
2023: Acquisition of Turning Point Therapeutics for $4.1B
Neurodegeneration Pipeline
Historical Programs
BMS has had neuroscience programs in the past, including early-stage research in Alzheimer's disease and Parkinson's disease. However, the company has reduced direct investment in neurodegenerative disease in recent years, focusing more on oncology, immunology, and cardiovascular diseases[@biomarin2026].
Celgene Heritage
The Celgene acquisition brought several assets with potential neurological applications:
Ozanimod: S1P receptor modulator approved for multiple sclerosis, studied for potential neuroprotective effects
CC-220 (iberdomide): Cereblon modulatory compound in development for MS and autoimmune conditions
CAR-T cell therapy platform: Originally developed for hematological malignancies, with potential for CNS applications
Current Activities
BMS-986089 (BMN 250): Collaboration with BioMarin on an enzyme replacement therapy for rare neurological diseases (discontinued)
Acquisition of Celgene (2019): Brought pipeline assets in multiple therapeutic areas
Exploratory neuroscience research: Internal discovery efforts in neurodegeneration remain active but not publicly disclosed
Business Development Strategy
BMS continues to evaluate external opportunities in neurodegeneration through partnerships and acquisitions. The company's expertise in protein degradation (through Celgene's cereblon platform) and cell therapy may provide future opportunities in Alzheimer's disease and Parkinson's disease[@bms2026].
Partnership Criteria
The company typically seeks:
Late-stage clinical assets with clear regulatory pathways
First-in-class or best-in-class potential
Synergies with existing oncology and immunology platforms
Accelerated approval opportunities
Pipeline Highlights
BMS currently has one of the largest pharmaceutical pipelines with over 50 compounds in clinical development. Key areas include:
Sotyktu (deucravacitinib): TYK2 inhibitor for psoriasis
Zeposia (ozanimod): S1P receptor modulator
Cardiovascular
mavacamta: Amyloidosis treatment (TTR stabilizer)
On anticoagulants and cardiovascular therapeutics
Strategic Outlook
While BMS has deprioritized direct investment in neurodegeneration, the company's expertise in protein homeostasis,免疫 modulation, and cell therapy positions it well for potential re-entry into the neurodegenerative disease space. The acquisition of late-stage neurological assets or partnerships with biotech companies could accelerate entry into Alzheimer's disease and Parkinson's disease markets, which represent multi-billion dollar opportunities.
The company's strong financial position ($12B+ cash reserves as of 2025) provides significant M&A capacity for strategic acquisitions in neuroscience if management decides to re-enter the space.